The management of factor VIII inhibitors in non-hemophilic patients.

Keyphrases

• Rheumatoid Arthritis 100%
• Hemophilia Patients 100%
• Factor VIII Inhibitor 100%
• Clot 50%
• Autoimmune Disease 50%
• Therapeutic Modalities 50%
• Prednisone 50%
• Illness 50%
• Cyclophosphamide 50%
• Systemic Lupus Erythematosus 50%
• Therapeutic Regimen 50%
• Coagulation 50%
• Titer 50%
• Immune Process 50%
• Associated Disorders 50%
• Major Bleeding 50%
• Bethesda 50%
• Clotting Factor Concentrates 50%
• Bleeding Episodes 50%
• Antihemophilic Factor 50%
• Plasmapheresis 50%
• Factor Concentrates 50%
• Factor VIII Concentrate 50%
• Inhibitor Formation 50%
• Stratagem 50%
• Porcine Factor VIII 50%
• Acute Bleeding 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Bleeding 100%
• Rheumatoid Arthritis 100%
• Blood Clotting Factor 8 100%
• Blood Clotting Factor 8 Inhibitor 100%
• Blood Clotting Factor 8 Concentrate 100%
• Inflammatory Arthritis 100%
• Side Effect 50%
• Cyclophosphamide 50%
• Azathioprine 50%
• Blood Clotting Factor Concentrate 50%
• Autoimmune Disease 50%
• Prednisone 50%
• Systemic Lupus Erythematosus 50%
• Diseases 50%